Novartis AG Company Profile (NYSE:NVS)

About Novartis AG

Novartis AG logoNovartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company's segments include Pharmaceuticals, Alcon and Sandoz. Its Pharmaceuticals segment is engaged in researching, developing, manufacturing, distributing and selling patented prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines. Its Alcon segment is engaged in developing, manufacturing and selling eye care products across the world. Its Sandoz segment is engaged in developing, manufacturing and marketing generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars and drug substances that are not protected by valid and enforceable third-party patents.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: NVS
  • CUSIP:
Key Metrics:
  • Previous Close: $77.28
  • 50 Day Moving Average: $73.82
  • 200 Day Moving Average: $75.00
  • 52-Week Range: $2,374,059,000.00 - $66.93
  • Trailing P/E Ratio: 27.60
  • Foreward P/E Ratio: 14.83
  • P/E Growth: 3.23
  • Market Cap: $183.47B
  • Outstanding Shares: 2,374,059,000
  • Beta: 0.73
  • Net Margins: 13.80%
  • Return on Equity: 15.37%
  • Return on Assets: 8.57%
  • Debt-to-Equity Ratio: 0.24%
  • Current Ratio: 1.12%
  • Quick Ratio: 0.84%
Additional Links:
Companies Related to Novartis AG:

Analyst Ratings

Consensus Ratings for Novartis AG (NYSE:NVS) (?)
Ratings Breakdown: 1 Sell Rating, 9 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.15)
Consensus Price Target: $87.33 (13.01% upside)

Analysts' Ratings History for Novartis AG (NYSE:NVS)
DateFirmActionRatingPrice TargetDetails
1/31/2017ArgusUpgradeHold -> BuyView Rating Details
1/25/2017J P Morgan Chase & CoReiterated RatingNeutralView Rating Details
1/17/2017Berenberg BankDowngradeBuy -> HoldView Rating Details
1/11/2017Credit Suisse GroupDowngradeOutperform -> NeutralView Rating Details
1/9/2017Deutsche Bank AGReiterated RatingNeutralView Rating Details
10/27/2016Societe GeneraleReiterated RatingHoldView Rating Details
10/16/2016Jefferies Group LLCReiterated RatingBuyView Rating Details
10/10/2016Chardan CapitalLower Price TargetBuy$95.00 -> $92.00View Rating Details
7/12/2016Bank of America CorpReiterated RatingHoldView Rating Details
5/24/2016Citigroup Inc.Reiterated RatingNeutralView Rating Details
5/2/2016Leerink SwannReiterated RatingHoldView Rating Details
4/22/2016Barclays PLCUpgradeUnderweight -> Equal WeightView Rating Details
4/12/2016Morgan StanleyDowngradeEqual Weight -> UnderweightView Rating Details
1/28/2016BNP ParibasDowngradeOutperform -> NeutralView Rating Details
1/7/2016Goldman Sachs Group, Inc. (The)Boost Price TargetNeutral$89.00 -> $92.00View Rating Details
11/23/2015VontobelDowngradeHoldView Rating Details
10/28/2015Sanford C. BernsteinLower Price TargetOutperform$102.00View Rating Details
10/28/2015Main First Bank AGDowngradeUnderperformView Rating Details
7/7/2015Oddo SecuritiesInitiated CoverageBuyView Rating Details
6/25/2015HSBC Holdings plcInitiated CoverageBuyView Rating Details
6/22/2015Bryan, Garnier & CoUpgradeNeutral -> BuyView Rating Details
3/4/2015NatixisUpgradeNeutral -> BuyView Rating Details
(Data available from 2/27/2015 forward)


Earnings History for Novartis AG (NYSE:NVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/25/2017Q416$1.12$1.12$12.44 billion$12.32 billionViewN/AView Earnings Details
10/25/2016Q316$1.19$1.23$12.24 billion$12.13 billionViewListenView Earnings Details
7/19/2016Q216$1.18$1.23$12.33 billion$12.47 billionViewListenView Earnings Details
4/21/2016Q116$1.18$1.17$11.90 billion$11.60 billionViewListenView Earnings Details
1/27/2016Q415$1.18$1.14$12.64 billion$12.52 billionViewListenView Earnings Details
10/27/2015Q315$1.31$1.27$12.66 billion$12.30 billionViewListenView Earnings Details
7/21/2015Q215$1.20$1.27$12.45 billion$12.70 billionViewListenView Earnings Details
4/23/2015Q115$1.10$1.33$12.90 million$11.94 billionViewN/AView Earnings Details
1/27/2015Q314$1.21$1.21$14.68 billion$14.63 billionViewN/AView Earnings Details
10/28/2014Q3$1.31$1.33$14.51 billion$14.70 billionViewN/AView Earnings Details
7/17/2014Q214$1.36$1.36$14.83 billion$14.64 billionViewN/AView Earnings Details
4/24/2014$1.27$1.31$14.25 billion$14.02 billionViewN/AView Earnings Details
1/29/2014Q413$1.27$1.20$15.16 billion$15.08 billionViewN/AView Earnings Details
10/22/2013Q313$1.31$1.26$14.28 billion$14.34 billionViewN/AView Earnings Details
7/17/2013Q213$1.29$1.30$14.39 billion$14.50 billionViewN/AView Earnings Details
4/24/2013Q113$1.28$1.32$14.02 million$14.02 billionViewN/AView Earnings Details
1/23/2013Q412$1.19$1.27$14.42 billion$14.80 billionViewN/AView Earnings Details
10/25/2012$1.34$1.34ViewN/AView Earnings Details
7/19/2012$1.33$1.38ViewN/AView Earnings Details
4/24/2012$1.30$1.27ViewN/AView Earnings Details
1/25/2012$1.26$1.23ViewN/AView Earnings Details
10/25/2011$1.45$1.45ViewN/AView Earnings Details
7/19/2011$1.46$1.48ViewN/AView Earnings Details
4/19/2011$1.30$1.41ViewN/AView Earnings Details
1/27/2011$1.25$1.14ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Novartis AG (NYSE:NVS)
Current Year EPS Consensus Estimate: $4.74 EPS
Next Year EPS Consensus Estimate: $5.21 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$1.17$1.18$1.17
Q2 20163$1.12$1.21$1.17
Q3 20162$1.19$1.20$1.20
Q4 20161$1.10$1.10$1.10
Q1 20171$1.15$1.15$1.15
Q2 20171$1.22$1.22$1.22
Q3 20171$1.25$1.25$1.25
Q4 20171$1.29$1.29$1.29
(Data provided by Zacks Investment Research)


Current Dividend Information for Novartis AG (NYSE:NVS)
Annual Dividend:$2.30
Dividend Yield:2.98%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:82.14% (Based on Trailing 12 Months of Earnings)
48.52% (Based on Current Year Consensus EPS Estimate)
44.15% (Based on Next Year Consensus EPS Estimate)

Dividend History for Novartis AG (NYSE:NVS)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Novartis AG (NYSE:NVS)
Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 9.82%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
2/17/2016Bioventures Ltd NovartisMajor ShareholderBuy375,000$8.00$3,000,000.00View SEC Filing  
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Novartis AG (NYSE:NVS)
DateHeadline logo7:10 am Novartis AG confirms the CHMP adopted a positive opinion recommending approval of Tafinlar in combination with Mekinist to treat patients with advanced or metastatic non- small cell lung cancer whose tumors express the BRAF V600 mut (NYSE:NVS) - February 25 at 6:34 PM logoNovartis Cancer Drug Zykadia Gets Priority Review (NVS) - Investopedia (NYSE:NVS) - February 24 at 8:00 PM logoEuropean advisory committee positive actions - Seeking Alpha (NYSE:NVS) - February 24 at 8:00 PM logoNovartis Cancer Drug Zykadia Gets Priority Review (NYSE:NVS) - February 24 at 8:00 PM logoNovartis Lung Cancer Drug Combo Gets CHMP Nod (NYSE:NVS) - February 24 at 8:00 PM logoLigand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates (NYSE:NVS) - February 24 at 8:55 AM logoRing the Register With These Upcoming Spinoffs (NYSE:NVS) - February 24 at 8:55 AM logoBlog Coverage Novartis Gains Priority Review from the FDA for its Cancer Drug Zykadia as a Frontline Treatment for ALK-positive Non-Small Cell Lung Cancer (NYSE:NVS) - February 24 at 8:55 AM logoNovartis wins CHMP nod for drug combo against some lung cancers (NYSE:NVS) - February 24 at 8:55 AM
News IconInvestors may be banking too much on Trump lifting earnings (NYSE:NVS) - February 24 at 12:02 AM
News IconAsian stocks drift higher as investors await Fed minutes (NYSE:NVS) - February 24 at 12:02 AM logo3:32 am Novartis receives Priority Review for Zykadia from FDA (NYSE:NVS) - February 24 at 12:02 AM
News IconTechnical Levels in View For Novartis AG (NVS) - Searcy News (NYSE:NVS) - February 23 at 7:00 PM logoNovartis cancer drug Zykadia gets FDA priority review - Reuters (NYSE:NVS) - February 23 at 7:00 PM
News IconForward Earnings Estimate of Novartis AG(NVS) - Highland Mirror (NYSE:NVS) - February 23 at 7:00 PM logoTeva Is Expected to See a Fall in Its Profit Margins in 2017 (NYSE:NVS) - February 23 at 7:00 PM logoManufacturing Delay Of Generic Drug From Pfizer Inc. (NYSE:PFE) A Relief For Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) (NYSE:NVS) - February 23 at 9:23 AM logoWall Street Sees Greener Territory (NYSE:NVS) - February 23 at 9:23 AM logoNovartis Says FDA Grants Priority Review For Expanded Use Zykadia (NYSE:NVS) - February 23 at 9:23 AM
News IconStarvation declared in South Sudan; UN says more than 5M at risk (NYSE:NVS) - February 23 at 12:03 AM
News IconWhat Does Carl Icahn Buying A Stake In Bristol-Myers Squibb Co (NYSE:BMY) Means to Investors? (NYSE:NVS) - February 22 at 7:00 PM
News IconNovartis AG (NYSE:NVS) Gapping Lower -1.10% - Aiken Advocate (NYSE:NVS) - February 21 at 5:56 PM
News IconNovartis AG (NYSE:NVS) Equity Price Target Fixed At $92 - Transcript Daily (NYSE:NVS) - February 18 at 6:07 PM logoBlog Coverage Ionis Pharma Closed on its Collaboration Agreement with Novartis Following Clearance under the Hart-Scott-Rodino Antitrust Improvements Act (NYSE:NVS) - February 17 at 4:36 PM
News IconAre Analysts Optimistic About Where Novartis AG (NYSE:NVS) is Heading? - Winfield Review (NYSE:NVS) - February 17 at 8:24 AM logoProlia Expected to Be a Significant Growth Driver for Amgen in 2017 (NYSE:NVS) - February 17 at 8:23 AM logoSaturna Capital CORP Buys NXP Semiconductors NV, Under Armour, Edwards Lifesciences, Sells ... (NYSE:NVS) - February 16 at 6:29 PM
News IconStocks Turns on Analysts Forecast: Novavax, Inc. (NASDAQ:NVAX), Novartis AG (NYSE:NVS) - Street Wise Report (blog) (NYSE:NVS) - February 16 at 6:29 PM
News IconTrading View on Shares of Novartis AG (NVS) - Providence Standard (NYSE:NVS) - February 16 at 6:28 PM logoNexthera Capital Lp Buys Novartis AG, Celgene, Alexion Pharmaceuticals, Sells GlaxoSmithKline PLC, Pfizer, Seattle ... - (NYSE:NVS) - February 16 at 6:28 PM logoNovartis Looks Like A $100 Stock - Seeking Alpha (NYSE:NVS) - February 16 at 6:28 PM logoNovartis AG (NYSE:NVS) Greater Use Of Technology In Transforming Medical Education (NYSE:NVS) - February 14 at 10:08 PM logoThese N.Y.C.-area doctors received the most payments from drug and device makers (NYSE:NVS) - February 14 at 10:08 PM
News IconNovartis AG (ADR) (NVS) Greater Use Of Technology In Transforming Medical Education (NYSE:NVS) - February 14 at 11:48 AM
News IconNovartis AG (NYSE:NVS) EPS Predicted At $1.29 - Transcript Daily (NYSE:NVS) - February 8 at 7:53 PM
News IconTechnical Levels in Review for Novartis AG (NVS) - Davidson Register (NYSE:NVS) - February 7 at 9:30 PM
News IconNovartis AG (NYSE:NVS) has industry P/E ratio of 29.05 - The Newburgh Press (NYSE:NVS) - February 7 at 12:04 AM logoNovartis’s Financial Guidance and Priorities for 2017 (NYSE:NVS) - February 3 at 7:45 PM logoWhy the Majority of Analysts Deem Novartis a ‘Buy’ (NYSE:NVS) - February 3 at 7:45 PM logoNovartis’s Valuation after the 4Q16 Results (NYSE:NVS) - February 3 at 7:45 PM
News IconAnalyst's keeping an Eye on: Novartis AG (NYSE:NVS), Target Corporation (NYSE:TGT) - The Newburgh Press (NYSE:NVS) - February 3 at 5:56 AM logoInside Novartis’s Generics Performance in 4Q16 (NYSE:NVS) - February 2 at 7:49 PM logoInside Novartis’s Eye Care Performance in 4Q16 (NYSE:NVS) - February 2 at 7:49 PM
News IconLarge Cap Drug Manufacturers – Major: Novartis AG (NYSE:NVS) (NYSE:NVS) - February 1 at 8:04 PM logoNovartis’s 4Q16 Earnings Meet Analysts’ Estimates (NYSE:NVS) - February 1 at 8:04 PM logoNovartis’s Innovative Medicines Segment in 4Q16 (NYSE:NVS) - February 1 at 8:04 PM logoNovartis Has Bright Future (NYSE:NVS) - February 1 at 8:04 PM logoNovartis Isn't Trading At An Attractive Valuation - Seeking Alpha (NYSE:NVS) - February 1 at 6:18 AM logoNovartis’ Votubia Drug Gets EU Approval (NVS) (NYSE:NVS) - January 31 at 7:55 PM
News IconTop Gainers of the Day: Novartis AG (NYSE:NVS) from Drug Manufacturers – Major (NYSE:NVS) - January 31 at 7:55 PM


What is Novartis AG's stock symbol?

Novartis AG trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How often does Novartis AG pay dividends? What is the dividend yield for Novartis AG?

Novartis AG announced an annual dividend on Friday, January 27th. Investors of record on Friday, March 3rd will be paid a dividend of $2.327 per share on Friday, March 3rd. The ex-dividend date of this dividend is Wednesday, March 1st.

Where is Novartis AG's stock going? Where will Novartis AG's stock price be in 2017?

13 brokers have issued twelve-month price targets for Novartis AG's shares. Their predictions range from $85.00 to $92.00. On average, they anticipate Novartis AG's stock price to reach $87.33 in the next twelve months.

What are analysts saying about Novartis AG stock?

Here are some recent quotes from research analysts about Novartis AG stock:

  • According to Zacks Investment Research, "Novartis’ fourth-quarter 2016 results were mixed with the company beating earnings estimates but missing on revenues. Concurrently, Novartis announced that it is mulling strategic options for Alcon which includes retaining the business or separation via a capital markets transaction such as a spin-off or an initial public offering. Given its dismal performance Alcon seems to be a laggard for quite some time now. The company’s shares have declined more sharply than the Large-Cap Pharmaceutical industry in the last one year. On a positive note, Cosentyx hit $1.1 billion in sales in 2016 thereby becoming a blockbuster drug for Novartis while Entresto is picking up gradually following the positive treatment guidelines in the U.S and Europe and ongoing field force expansion. The oncology portfolio (excluding Gleevec) also looks solid, driven by new assets and Jakavi. We are also impressed by the strong biosimilars portfolio." (1/30/2017)

  • Citigroup Inc. analysts commented, "The ongoing action of the formidable State Attorney General (SAG) of the Southern District of NY, Preet Bharara, casts a reputational shadow over the incumbent Novartis Chairman and CEO, who both had operational responsibilities at Novartis during the alleged period of widespread kickbacks."Further Details"Similar to GlaxoSmithKline plc (ADR) (NYSE: GSK) before it, Novartis faces a high probability of significant fines (in excess of $2 billion) as well as an additional punitive Corporate Integrity Agreement providing material risk to already lowered consensus Entresto (cardiovascular) estimates," analyst Baum wrote in a note to clients.The analyst cut his 2025 Entresto estimate to $2 billion from $10 billion.Related Link: Novartis Shares Downgraded, Leerink Says "Consensus Still Way Too High"The State Attorney General alleges "Novartis allowed kickbacks or inducements to prescribers of their cardiovascular drug through a stream of round table and education events, typically at restaurants," Baum elaborated.The analyst continued, "The provision of nine years' worth of records and salesmen testimony could indeed generate sufficient evidence to ensure a successful prosecution. The highest individual payment under the FCA was a $2 billion settlement from GSK in 2012 in relation to extensive off-label promotion over a prolonged period."Much more importantly, the DoJ imposed a strict CIA on GSK that continues to negatively impact the performance of GSK primary care portfolio, including the newly launched respiratory products (Breo and Anoro)."We think the issuance of a GSK-like CIA to Novartis would likely severely impact Novartis' earnings and valuation outlook given the important anticipated contribution of future Entresto revenues (cardiovascular disease)," Baum noted."It is possible that Novartis's decision to delay aggressive marketing of Entresto in the US was related to the ongoing SAG investigation," (3/29/2016)

Who owns Novartis AG stock?

Novartis AG's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (0.62%), Loomis Sayles & Co. L P (0.26%), State Street Corp (0.13%), Renaissance Technologies LLC (0.10%), Federated Investors Inc. PA (0.08%) and Dimensional Fund Advisors LP (0.05%). Company insiders that own Novartis AG stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis.

Who sold Novartis AG stock? Who is selling Novartis AG stock?

Novartis AG's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, First Republic Investment Management Inc., Osterweis Capital Management Inc., Brown Advisory Inc., Scharf Investments LLC, Capital Guardian Trust Co. and Guardian Capital LP.

Who bought Novartis AG stock? Who is buying Novartis AG stock?

Novartis AG's stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Federated Investors Inc. PA, Loomis Sayles & Co. L P, Davis Selected Advisers, Edge Asset Management Inc., Van ECK Associates Corp, Thornburg Investment Management Inc. and Gratus Capital LLC. Company insiders that have bought Novartis AG stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis.

How do I buy Novartis AG stock?

Shares of Novartis AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Novartis AG stock cost?

One share of Novartis AG stock can currently be purchased for approximately $77.28.

Novartis AG (NYSE:NVS) Chart for Monday, February, 27, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Earnings History Chart

Earnings by Quarter for Novartis AG (NYSE:NVS)

Dividend History Chart

Dividend Payments by Quarter for Novartis AG (NYSE:NVS)

Last Updated on 2/27/2017 by Staff